The method of obtaining precipitating sera for species identification of meat of domestic and wild animals

 

(57) Abstract:

The invention relates to veterinary medicine, in particular to the examination of animal products. To expand the technological capabilities as antigen used the blood of animals, such as rats, nutria or frogs, and injected subcutaneously at intervals. The reaction of precipitation of the most accurate and fast method in contrast to other known methods and used in forensics.

The invention relates to the field of veterinary medicine, in particular to the examination of animal products.

Known invention [see USSR, N 1018643, CL. A 61 K 39/395, 1984], where mnogoseriynuyu serum obtained by injection of the complex antigen-antibody with subsequent extraction of the immune serum, and its treatment of the specific antigen and the introduction of the received complex animal producer.

Also known is a method of obtaining specific sera [specific sera to immunoglobulinum different classes author: C. M. Janenko, A. F., mogilino, W-l "veterinary medicine", 1981, S. 27 - 28, author of taken for prototype].

A disadvantage of the known technological solutions I have animals such as nutria, rats and frogs, which are necessary for the differential diagnosis with the purpose of species identification of meat, in connection with the expansion of imported imports of food products, in particular the legs of frogs that do not have the rear extremities and skin, which could roughly determine whether meat, in addition, frozen meat color changes, so you can easily make a mistake in the differential diagnosis, because the structure of the hind limbs of rats and otters at the age of 14 days is similar to the hind limbs of frogs.

Technological solution to the problem is the expansion of technological capabilities.

The task is achieved in that in the method of producing antisera for species identification of meat of domestic and wild animals, including subcutaneous and intramuscular injection of antigen laboratory animal, such as rabbit with subsequent blood sampling from the same animal as the antigen used the blood of animals such as nutria or rats or frogs, and injected subcutaneously every 5 days in the following doses 0,2 - 0,3; 0,4 - 0,5; 0,6 - 0,7; 0,8 - 0,9 ml, then 1 - 1.2 ml intramuscularly one introduction, and the last three, 1,4 - 1,5 ml Not p, is it due to selected doses of antigen is expanding technological opportunities for species identification of meat.

According to the patent and technical literature is not detected by the claimed combination of features that allows us to judge about the level of invention proposals.

The method is as follows:

Blood, frogs, rats, and nutria was administered to rabbits with an interval of 5 days in the amount of 0,3; 0,5; 0,7; 0,9 ml for each injection, 1 ml intramuscularly in the thigh and three last injection of 1.5 ml with an interval of 5 days. 10 days after the last injection of antigen, detection of a sufficient titer of serum [1: 1000] took the blood of the rabbit heart. Taken from blood received anticigarette.

An example of a specific implementation of the

To obtain precipitating sera species identification of meat, such as frogs. For this purpose the rabbit was injected subcutaneously with 0.3 ml of whole blood frogs and after 5 days again the same rabbit was injected with 0.5 ml of whole blood frog podlin, then similarly 0.7 and 0.9 ml. of 5 days after the last subcutaneous injection was administered intramuscularly 1 ml whole blood in the thigh and three pic is of varodi for each kind of animal [nutria, rats, etc.] took a separate laboratory animal - rabbits with a weight of not less than 2 kg.

The antisera used for the reaction in this case had specificity, i.e., gave a precipitate only with the serum of the species of animal, the blood of which was hyperimmunization.

The serum had a high sensitivity and positive even when significant dilution of solution used proteins [meat extracts] . The titer of the antisera was determined by serial dilutions of the serum of the same animal species, against which was prepared this anticigarette. Suitable for use anticavity with titre not less than 1:1000, provided that it reacts only with the serum of a certain type of animal.

Study of the meat by the method of precipitation was carried out as follows. Meat, freed from fat and ligaments, finely sliced and within 3 h insisted in saline solution. The extract obtained was filtered and the concentration of protein in it 1: 1000, the level of dilution was determined using capillary samples. For this glass capillary with a length of about 10 cm was dipped one end into the extract liquid was sucked in an amount such that the energy Kapil is also included in the capillary. At the place of contact of the extract with acid formed white ring of precipitated protein. The extract was diluted up until the last sample did not appear barely visible ring, which corresponds to the protein content in the extract of 1:1000.

Diluted extract was injected in Orangutans tube in the amount of 0.9 ml and in the third, the same serum of the animal, the flesh of which is intended to detect in the study. The appearance of rings in the first and third tubes for 1 h indicated that the analyzed meat belongs to this type of animal. Ring only in the third test tube meant negative, and the study was repeated with another anticorodal.

The most reliable when species identification of meat is the reaction of precipitation, which is undeniable in forensics. The precipitation reaction is the most accurate and rapid method in contrast to other known methods.

The method of obtaining precipitating sera for species identification of meat of domestic and wild animals, including subcutaneous and intramuscular injection of antigen laboratory animal with subsequent blood sampling from the same animal injected subcutaneously every 5 days in the following doses: 0.2 to 0,3; 0,4 - 0,5; 0,6 - 0,7; 0,8 - 0,9 ml and 1 - 1.2 ml intramuscularly at intervals of 5 days, then after the last injection no earlier than 10 days take blood from the heart of the laboratory animal.

 

Same patents:
The invention relates to chemical-pharmaceutical industry, medicine and relates to antiviral, antimicrobial and protivokariosnoe tools

The invention relates to medicine, namely to clinical immunology, and the development and use of a new immunoglobulin drug against hepatitis B
The invention relates to the production of specific immunoglobulins for intravenous
The invention relates to the production of specific immunoglobulins for intravenous

The invention relates to biotechnology

The invention relates to humanized antibodies and their binding proteins which are capable of contacting the T cell with certain variable beta chain

The invention relates to medicine, in particular to Oncology and immunology, and for the treatment of b-cell lymphoma

The invention relates to medicine, in particular to immunology, and can be used for neutralization of TNFy patient in need of such neutralization
The invention relates to medicine, specifically to medicinal drug on the basis of immunoglobulins

The invention relates to biotechnology and immunology, and can be used to obtain stable forms of immunobiological preparations that retain their specific characteristics in a long time

FIELD: genetic engineering, immunology, medicine.

SUBSTANCE: invention relates to new antibodies directed against antigenic complex CD3 and can be used in therapeutic aims. Antibody IgG elicits the affinity binding with respect to antigenic complex CD3 wherein heavy chain comprises skeleton of the human variable region in common with at least one CD3 taken among amino acid sequences SEQ ID NO 2, 4 and 6 and their corresponding conservatively modified variants. Light chain comprises skeleton of the rodent variable region in common with at least one CD3 taken among amino acid sequences SEQ ID NO 8, 10 and 12 and their corresponding conservatively modified variants. Antibody is prepared by culturing procaryotic or eucaryotic cell co-transformed with vector comprising recombinant nucleic acid that encodes antibody light chain and vector comprising recombinant nucleic acid that encodes antibody heavy chain. Antibody is administrated in the patient suffering with malignant tumor or needing in immunosuppression in the effective dose. Invention provides preparing chimeric antibodies against CD3 that are produced by expression systems of procaryotic and eucaryotic cells with the enhanced yield.

EFFECT: improved preparing methods, valuable medicinal properties of antibody.

33 cl, 5 dwg, 1 ex

FIELD: medicine, pharmaceutical industry and technology, pharmacy.

SUBSTANCE: invention relates to a composition eliciting an antiviral effect. The composition comprises hydrophilic conglomerate of immunoglobulins consortium adsorbed with polyethylene glycol 4000-6000, recombinant interferon-α2 and a special additive taken among the following substances: glycine, glucose, maltose, sodium chloride taken in the definite ratio of components. Invention provides elevating solubility of composition eliciting an antiviral effect and enhanced release of biologically active substances to solution.

EFFECT: valuable medicinal properties of composition.

5 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a composition eliciting an antibacterial effect. Composition comprises hydrophilic conglomerate of immunoglobulins consortium adsorbed with polyethylene glycol 4000-6000 and a special additive taken among the following substances: glycine, glucose, maltose, sodium chloride taken in the definite ratio of components. Invention provides sufficient desorption of biologically active substances in resuspending the composition eliciting an antibacterial effect and comprising consortium of immunoglobulins.

EFFECT: valuable medicinal properties of composition.

5 ex

FIELD: immunology.

SUBSTANCE: the innovation deals with new immunogenic conjugates of beta-propionamide-bound polysaccharide and N-propionamide-bound oligosaccharide with protein, and the method to obtain these conjugates has been suggested, as well. Conjugates should be applied to obtain vaccines against infectious diseases and cancer that enables to broaden the number of preparations applied in treating the above-mentioned diseases.

EFFECT: higher efficiency.

1 dwg, 2 ex, 8 tbl

FIELD: microbiology and immunology, in particular immunodiagnosis.

SUBSTANCE: atypical strain of melioidose Burkholderia pseudomallei-111-6-1 with altered phenotype defected with respect to synthesis of 8 antigen and acting as immunosuppressor is used as antigen for animal immunization. Immune serum is obtained after 2 immunization cycles of animal-producer with titer in gel immunodiffusion reaction not less than 1:128.

EFFECT: immune serum with increased specific activity.

2 tbl, 2 ex

FIELD: medicine and immunology, in particular treatment and prevention immunodeficiency conditions and diseases associated with bacterial or viral aggression.

SUBSTANCE: claimed method includes administration to a patient immunoglobulin drug (e.g., pharmaceutical composition containing 6-12 % of specific heterologous secreted immunoglobulin A, isolated from milk or foremilk of immunized ungulates). Administration is performed parenterally wherein single dose is at least 10 IU/kg of patient weight for treatment or at least 5 IU/kg for prophylaxis; or perorally in dose of 0.2-0.5 g and/or topically one-two times per day for 1-5 days. Method of present invention makes it possible to decrease dose of administrating immunoglobulin due to prolonged retention of its high titers in body fluids.

EFFECT: enlarged range of application and assortment of immunoglobulin drugs.

4 cl, 5 ex

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with cryoprotective ointment containing recombinant interferon-α2. The suggested cryoprotective ointment contains recombinant interferon-α2, glycerol, polyethylene glycol 300-6000, polyglucin, buffered 0.02%-Trilon B solution at pH of 5.5-7.0 and ointment foundation at a certain content of components per 1.0 g ointment. Additionally, cryoprotective ointment could contain glycine 3,7-bis(dimethylamino)phenothiazonium chloride, dry immunoglobulin preparation or dry immunoglobulin preparation for enteral application. Ointment foundation of cryoprotective ointment could contain water-free lanolin, Vaseline and Vaseline oil, at the following ratio of components: 2.5;3.5:1 - 6.5:0.5:1. The innovation provides maximal safety of recombinant interferon-α2 activity in cryoprotective ointment at multiple alteration of positive and negative environmental temperature and at keeping cryoprotective ointment under these conditions.

EFFECT: higher efficiency of application.

8 cl, 8 ex

FIELD: medicine, pharmaceutics, pharmacology.

SUBSTANCE: one should apply mammalian anti-HBP-antibodies. The ways are being suggested to identify monoclonal antibody bound, at least, with one epitope upon native HBP (heparin-binding protein) and methods to detect whether a mammal produces HBR being bound with a monoclonal antibody and, also, the kits for the above-mentioned purpose. The present innovation provides the opportunity to apply the mentioned antibodies in preventing and treating disorders associated with bradykinin releasing.

EFFECT: higher efficiency of application.

25 cl, 11 dwg, 3 ex, 1 tbl

FIELD: veterinary science.

SUBSTANCE: animals should be introduced with antihistamine serum (AHS) subcutaneously at the dosage of 4.0-5.0 ml in combination with myxoferon at the quantity of 60-75 dosages and vitamin C at the dosage of 1.0-1.5 ml/animal, once daily, thrice at interval of 5-7 d. Application of AHS in combination with myxoferon and ascorbic acid provides active stimulation of immunological reactivity, increases total body resistance I animals and causes no toxic effects and allergic reactions.

EFFECT: higher efficiency of correction.

3 tbl

FIELD: immunology, biotechnology, medicine.

SUBSTANCE: invention relates to antiidiotypical monoclonal antibody or fragment thereof for BSW17 antibody effecting on LgE Cε3-region bonding to high affinity LgE receptor. Amino acid sequence is as described in specification. antiidiotypical antibody is useful as pharmaceutical composition ingredient for LgE-mediated disease treatment. Invention make in possible to prevent allergic disorders and inflammations due to inhibiting interaction between LgE Cε3-region with high affinity receptor by claimed antibody.

EFFECT: new agent for allergic and inflammation disorder treatment.

7 cl, 32 dwg, 5 tbl, 10 ex

Up!